AKArianne van Koppen

Arianne van Koppen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arianne van Koppen has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A novel mouse model for cardiovascular-kidney-metabolic syndrome: Bridging metabolic, renal and cardiac dysfunction

    by Arianne van Koppen, José A. Inia, Romer A. Gonzalez-Villalobos, Anke M. Smits, Andrea R. Nawrocki, Simon A. Hinke, Joline Attema, Christa de Ruiter, Tri Q. Nguyen, Amelie Dendooven, et al.


  • Open Access

    Fibrogenic Gene Signature as Early Prediction for the Efficacy of Pharmacological Interventions for MASH ‐Associated Fibrosis

    by José A. Inia, Martine C. Morrison, Arianne van Koppen, Eveline Gart, Martien P. M. Caspers, Aswin L. Menke, Nicole Worms, Robert Kleemann, Lars Verschuren, J. Wouter Jukema, et al.

    The incidence of metabolic dysfunction‐associated steatohepatitis (MASH) and associated liver fibrosis is rapidly increasing, while pharmacological treatment options remain limited. Despite great efforts in developing novel MASH therapeutics, many investigative therapeutics that reduced fibrosis in preclinical models ultimately failed in clinical trials. To this end, we explored the possibility of predicting the efficacy of therapeutics by evaluating changes in the expression of a fibrogenic gene signature in the early stages of disease development and before effects on pathology become evident. Ldlr−/−.Leiden mice were fed a high‐fat diet (HFD) to induce obesity and MASH. Mice were subsequently treated for 4 weeks with various therapeutics with established efficacy (obeticholic acid) or lack of efficacy (cenicriviroc and pioglitazone) to study their anti‐fibrotic potential. Expression of a fibrogenic gene signature was evaluated, which predicts profibrotic processes before histopathologic fibrosis develops. The predictions were compared with a long‐term experiment reaching histological fibrosis endpoints. Cenicriviroc and pioglitazone did not affect HFD‐induced fibrosis signature, indicative of no effect of these treatments on active fibrosis processes. Consistently, in the long‐term treatment study, both cenicriviroc and pioglitazone did not affect HFD‐induced histologically measured fibrosis. In contrast, obeticholic acid improved the fibrogenic gene signature to a healthier state compared to untreated HFD controls. These early gene expression changes aligned with long‐term histological fibrosis endpoints and clinical data on these investigative therapeutics. This study highlights the potential of using short‐term studies and applying a fibrogenic gene signature as an early screening tool to investigate the efficacy of investigative drugs on MASH‐associated fibrosis. This signature, which is based on the active fibrosis processes in humans, may allow rapid screening of therapeutics, or combinations thereof, when used in a translational mouse model.


  • Open Access

    Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD

    by Lars Verschuren, Anne Linde Mak, Arianne van Koppen, Serdar Özsezen, Sonia Difrancesco, Martien P. M. Caspers, Jessica Snabel, David van der Meer, Anne-Marieke van Dijk, Elias Badal Rashu, et al.

    Accurate non-invasive biomarkers to diagnose metabolic dysfunction-associated steatotic liver disease (MASLD)-related fibrosis are urgently needed. This study applies a translational approach to develop a blood-based biomarker panel for fibrosis detection in MASLD. A molecular gene expression signature identified from a diet-induced MASLD mouse model (LDLr−/−.Leiden) is translated into human blood-based biomarkers based on liver biopsy transcriptomic profiles and protein levels in MASLD patient serum samples. The resulting biomarker panel consists of IGFBP7, SSc5D and Sema4D. LightGBM modeling using this panel demonstrates high accuracy in predicting MASLD fibrosis stage (F0/F1: AUC = 0.82; F2: AUC = 0.89; F3/F4: AUC = 0.87), which is replicated in an independent validation cohort. The overall accuracy of the model outperforms predictions by the existing markers Fib-4, APRI and FibroScan. In conclusion, here we show a disease mechanism-related blood-based biomarker panel with three biomarkers which is able to identify MASLD patients with mild or advanced hepatic fibrosis with high accuracy.


  • Open Access

    Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis

    by Anita M. van Den Hoek, Serdar Özsezen, Martien P. M. Caspers, Arianne van Koppen, Roeland Hanemaaijer, Lars Verschuren

    The prevalence of non-alcoholic steatohepatitis (NASH) is rapidly increasing and associated with cardiovascular disease (CVD), the major cause of mortality in NASH patients. Although sharing common risk factors, the mechanisms by which NASH may directly contribute to the development to CVD remain poorly understood. The aim of this study is to gain insight into key molecular processes of NASH that drive atherosclerosis development. Thereto, a time-course study was performed in Ldlr−/−.Leiden mice fed a high-fat diet to induce NASH and atherosclerosis. The effects on NASH and atherosclerosis were assessed and transcriptome analysis was performed. Ldlr−/−.Leiden mice developed obesity, hyperlipidemia and insulin resistance, with steatosis and hepatic inflammation preceding atherosclerosis development. Transcriptome analysis revealed a time-dependent increase in pathways related to NASH and fibrosis followed by an increase in pro-atherogenic processes in the aorta. Gene regulatory network analysis identified specific liver regulators related to lipid metabolism (SC5D, LCAT and HMGCR), inflammation (IL1A) and fibrosis (PDGF, COL3A1), linked to a set of aorta target genes related to vascular inflammation (TNFA) and atherosclerosis signaling (CCL2 and FDFT1). The present study reveals pathogenic liver processes that precede atherosclerosis development and identifies hepatic key regulators driving the atherogenic pathways and regulators in the aorta.


  • Unraveling the transcriptional dynamics of NASH pathogenesis affecting atherosclerosis development

    by Anita M. van Den Hoek, Serdar Özsezen, Martien P.M Caspers, Geurt Stokman, Arianne van Koppen, Roeland Hanemaaijer, Lars Verschuren

  • Open Access

    Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model

    by Arianne van Koppen, Lars Verschuren, Anita M. van Den Hoek, Joanne Verheij, Martine C. Morrison, Kelvin Li, Hiroshi Nagabukuro, Adalberto Costessi, Martien P.M. Caspers, Tim J. van Den Broek, et al.


  • Open Access

    Arrhythmogenic Remodeling in Murine Models of Deoxycorticosterone Acetate-Salt-Induced and 5/6-Subtotal Nephrectomy-Salt-Induced Cardiorenal Disease

    by Magda S.C. Fontes, Diana A. Papazova, Arianne van Koppen, Sanne de Jong, Sanne M. Korte, Lennart G. Bongartz, Tri Q. Nguyen, Marti F.A. Bierhuizen, Teun P. de Boer, Toon A.B. van Veen, et al.

    Background: Renal failure is associated with adverse cardiac remodeling and sudden cardiac death. The mechanism leading to enhanced arrhythmogenicity in the cardiorenal syndrome is unclear. The aim of this study was to characterize electrophysiological and tissue alterations correlated with enhanced arrhythmogenicity in two distinct mouse models of renal failure. Methods: Thirty-week-old 129Sv mice received a high-salt diet and deoxycorticosterone acetate (DOCA) for 8 weeks, followed by an additional period of high-salt diet for 27 weeks (DOCA-salt aged model). Adult CD-1 mice were submitted to 5/6-subtotal nephrectomy (SNx) and treated for 11 weeks with a high-salt diet (SNx-salt adult model). Vulnerability to arrhythmia as well as conduction velocities (CVs) of the hearts were determined ex vivo with epicardial mapping. Subsequently, the hearts were characterized for connexin 43 (Cx43) and fibrosis. Results: DOCA-salt and SNx-salt mice developed renal dysfunction characterized by albuminuria. Heart, lung and kidney weights were increased in DOCA-salt mice. Both DOCA-salt and SNx-salt mice were highly susceptible to ventricular arrhythmias. DOCA-salt mice had a significant decrease in both longitudinal and transversal CV in the left ventricle. Histological analysis revealed a significant reduction in Cx43 expression as well as an increase in interstitial fibrosis in both DOCA-salt and SNx-salt mice. Conclusion: DOCA-salt and SNx-salt treatment induced renal dysfunction, which resulted in structural and electrical cardiac remodeling and enhanced arrhythmogenicity. The reduced Cx43 expression and increased fibrosis levels in these hearts are likely candidates for the formation of the arrhythmogenic substrate.


  • Open Access

    Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

    by Arianne van Koppen, Diana A Papazova, Nynke R Oosterhuis, Hendrik Gremmels, Rachel H Giles, Joost O Fledderus, Jaap A Joles, Marianne C Verhaar

    Introduction: Healthy bone marrow cell (BMC) infusion improves renal function and limits renal injury in a model of chronic kidney disease (CKD) in rats. However, BMCs derived from rats with CKD fail to retain beneficial effects, demonstrating limited therapeutic efficacy. Statins have been reported to improve cellular repair mechanisms. Methods: We studied whether exposing CKD rat BMCs ex vivo to pravastatin improved their in vivo therapeutic efficacy in CKD and compared this to systemic in vivo treatment. Six weeks after CKD induction, healthy BMCs, healthy pravastatin-pretreated BMCs, CKD BMCs or CKD pravastatin-pretreated BMCs were injected into the renal artery of CKD rats. Results: At 6 weeks after BMC injection renal injury was reduced in pravastatin-pretreated CKD BMC recipients vs. CKD BMC recipients. Effective renal plasma flow was lower and filtration fraction was higher in CKD BMC recipients compared to all groups whereas there was no difference between pravastatin-pretreated CKD BMC and healthy BMC recipients. Mean arterial pressure was higher in CKD BMC recipients compared to all other groups. In contrast, 6 weeks of systemic in vivo pravastatin treatment had no effect. In vitro results showed improved migration, decreased apoptosis and lower excretion of pro-inflammatory Chemokine (C-X-C Motif) Ligand 5 in pravastatin-pretreated CKD BMCs. Conclusions: Short ex vivo exposure of CKD BMC to pravastatin improves CKD BMC function and their subsequent therapeutic efficacy in a CKD setting, whereas systemic statin treatment did not provide renal protection.


  • Open Access

    Cell-based therapies for experimental chronic kidney disease: a systematic review and meta-analysis

    by Diana A. Papazova, Nynke R. Oosterhuis, Hendrik Gremmels, Arianne van Koppen, Jaap A. Joles, Marianne C. Verhaar

    Cell-based therapy is a promising strategy for treating chronic kidney disease (CKD) and currently the focus of preclinical studies. We performed a systematic review and meta-analysis to evaluate efficacy of cell-based therapy in preclinical (animal) studies of CKD, and determined factors affecting cell-based therapy efficacy in order to guide future clinical trials. 71 articles met inclusion criteria. Standardized mean differences (SMD) and 95% confidence interval (CI) were calculated for outcome parameters including plasma urea, plasma creatinine, urinary protein, blood pressure, glomerular filtration rate, glomerulosclerosis and interstitial fibrosis. Sub-analysis for each outcome measure was performed for model-related (species, gender, model and timing of therapy) and cell-related (cell type, -condition, -origin, administration route and regime of therapy) factors. Overall, meta-analysis showed that cell-based therapy reduced development and progression of CKD. This was most prominent for urinary protein (SMD 1.34 95% CI [1.00-1.68]) and urea (1.09, 0.66-1.51), both p<0.001. Changes in plasma urea associated with changes in both glomerulosclerosis and interstitial fibrosis. Sub-analysis showed that cell type (bone marrow derived progenitors and mesenchymal stromal cells being most effective) and administration route (intravenous or renal artery injection) were significant predictors of therapeutic efficacy. Timing of therapy in relation to clinical manifestation of disease, and cell-origin and -dose, were not associated with efficacy. Our meta-analysis confirms that cell-based therapies improve impaired renal function and morphology in preclinical models of CKD. Our analyses can be used to optimize experimental interventions and thus support both improved preclinical research and development of cell-based therapeutic interventions in clinical setting.


  • Open Access

    Maintenance of Hypertensive Hemodynamics Does Not Depend on ROS in Established Experimental Chronic Kidney Disease

    by Diana A. Papazova, Arianne van Koppen, Maarten P. Koeners, Ronald L. Bleys, Marianne C. Verhaar, Jaap A. Joles

    While the presence of oxidative stress in chronic kidney disease (CKD) is well established, its relation to hypertensive renal hemodynamics remains unclear. We hypothesized that once CKD is established blood pressure and renal vascular resistance (RVR) no longer depend on reactive oxygen species. CKD was induced by bilateral ablation of 2/3 of each kidney. Compared to age-matched, sham-operated controls all ablated rats showed proteinuria, decreased glomerular filtration rate (GFR), more renal damage, higher mean arterial pressure (MAP), RVR and excretion of oxidative stress markers and hydrogen peroxide, while excretion of stable nitric oxide (NO) metabolites tended to decrease. We compared MAP, RVR, GFR and fractional excretion of sodium under baseline and during acute Tempol, PEG-catalase or vehicle infusion in rats with established CKD vs. controls. Tempol caused marked reduction in MAP in controls (96±5 vs.79±4 mmHg, P<0.05) but not in CKD (130±5 vs. 127±6 mmHg). PEG-catalase reduced MAP in both groups (controls: 102±2 vs. 94±4 mmHg, P<0.05; CKD: 118±4 vs. 110±4 mmHg, P<0.05), but did not normalize MAP in CKD rats. Tempol and PEG-catalase slightly decreased RVR in both groups. Fractional excretion of sodium was increased by both Tempol and PEG-catalase in both groups. PEG-catalase decreased TBARS excretion in both groups. In sum, although oxidative stress markers were increased, MAP and RVR did not depend more on oxidative stress in CKD than in controls. Therefore reactive oxygen species appear not to be important direct determinants of hypertensive renal hemodynamics in this model of established CKD.